Loading...
XNYSTMO
Market cap200bUSD
Dec 20, Last price  
524.05USD
1D
1.42%
1Q
-14.61%
Jan 2017
271.40%
Name

Thermo Fisher Scientific Inc

Chart & Performance

D1W1MN
XNYS:TMO chart
P/E
33.44
P/S
4.68
EPS
15.67
Div Yield, %
0.26%
Shrs. gr., 5y
-0.90%
Rev. gr., 5y
11.96%
Revenues
42.86b
-4.58%
2,205,995,0002,633,027,0003,791,617,0009,746,400,00010,498,000,00010,109,700,00010,788,700,00011,725,900,00012,509,900,00013,090,300,00016,889,600,00016,965,400,00018,274,100,00020,918,000,00024,358,000,00025,542,000,00032,218,000,00039,211,000,00044,915,000,00042,857,000,000
Net income
6.00b
-13.74%
361,837,000223,218,000168,935,000761,100,000994,200,000850,300,0001,035,600,0001,329,900,0001,177,900,0001,273,300,0001,894,400,0001,975,400,0002,021,800,0002,225,000,0002,938,000,0003,696,000,0006,375,000,0007,725,000,0006,950,000,0005,995,000,000
CFO
8.41b
-8.17%
264,510,000270,913,000405,654,0001,483,500,0001,420,200,0001,659,200,0001,497,800,0001,691,000,0002,039,500,0002,010,700,0002,619,600,0002,816,900,0003,156,300,0004,005,000,0004,543,000,0004,973,000,0008,289,000,0009,543,000,0009,154,000,0008,406,000,000
Dividend
Sep 13, 20240.39 USD/sh
Earnings
Jan 31, 2025

Profile

Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
URL
https://www.thermofisher.com/
IPO date
Aug 27, 1980
Employees
130,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
42,857,000
-4.58%
44,915,000
14.55%
39,211,000
21.71%
Cost of revenue
27,081,000
26,886,000
20,383,000
Unusual Expense (Income)
NOPBT
15,776,000
18,029,000
18,828,000
NOPBT Margin
36.81%
40.14%
48.02%
Operating Taxes
284,000
703,000
1,109,000
Tax Rate
1.80%
3.90%
5.89%
NOPAT
15,492,000
17,326,000
17,719,000
Net income
5,995,000
-13.74%
6,950,000
-10.03%
7,725,000
21.18%
Dividends
(523,000)
(455,000)
(395,000)
Dividend yield
0.25%
0.21%
0.15%
Proceeds from repurchase of equity
(3,000,000)
(3,000,000)
18,805,000
BB yield
1.46%
1.38%
-7.10%
Debt
Debt current
3,609,000
5,579,000
2,537,000
Long-term debt
62,616,000
57,704,000
33,536,000
Deferred revenue
(7,119,000)
(52,830,000)
Other long-term liabilities
4,642,000
4,270,000
48,993,000
Net debt
58,148,000
54,605,000
31,533,000
Cash flow
Cash from operating activities
8,406,000
9,154,000
9,543,000
CAPEX
(1,479,000)
(2,243,000)
(2,523,000)
Cash from investing activities
(5,142,000)
(2,159,000)
(21,932,000)
Cash from financing activities
(3,622,000)
(2,810,000)
6,581,000
FCF
16,082,000
15,780,000
13,761,000
Balance
Cash
8,077,000
8,524,000
4,477,000
Long term investments
154,000
63,000
Excess cash
5,934,150
6,432,250
2,579,450
Stockholders' equity
44,689,000
42,521,000
36,054,000
Invested Capital
80,466,850
76,441,750
77,807,550
ROIC
19.75%
22.46%
27.55%
ROCE
17.86%
21.03%
22.35%
EV
Common stock shares outstanding
388,000
394,000
397,000
Price
530.79
-3.61%
550.69
-17.47%
667.24
43.25%
Market cap
205,946,520
-5.08%
216,971,860
-18.09%
264,894,280
42.53%
EV
264,201,520
274,845,860
298,940,280
EBITDA
19,182,000
21,410,000
21,420,000
EV/EBITDA
13.77
12.84
13.96
Interest
1,375,000
726,000
536,000
Interest/NOPBT
8.72%
4.03%
2.85%